By contrast, targeting specific pathways, on which leukemia cells rely, has been more promising for drug development, exemplified by venetoclax targeting BCL-2 or PI3K/AKT/mTOR inhibitors7,8,10. This evidence concerns the gene MTOR and leukemia.